


Name: Survodutide Cat#: EX-A7878

Chemical Structure:



Sequence:	His-(1-amino-1-cyclobutanecarboxylic acid)-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Arg-Ala-Ala-Lys-Asp-Phe-Ile-Lys(Gly- Gly-Ser-Gly-Ser-Gly-γ-Glu-17-carboxyheptadecanoyl)-Trp-Leu-Glu-Ser-Ala-NH ₂
-----------	--

Molecular Weight	4231.6274	Storage	1 year 0- 4°C powder
Formula	C ₁₉₂ H ₂₈₉ N ₄₇ O ₆₁		2 years -20°C powder
CAS No.	2805997-46-8	Synonyms	6 months -80°C in solvent
			BI 456906

Solubility (25°C) *	In vitro	DMSO	N/A
		Ethanol	N/A
Water		Soluble	
	In vivo (should be freshly prepared each time)		

* <1 mg/ml means slightly soluble or insoluble.
 * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions:

Concentration	Mass	1 mg	5 mg	10 mg
	Volume			
1 mM		0.2363 mL	1.1816 mL	2.3632 mL
5 mM		0.0473 mL	0.2363 mL	0.4726 mL
10 mM		---	---	---

 H₂O :

*The above data is based on the product molecular weight 4231.62.

Biological Activities:

Description
Survodutide (BI 456906) is a novel glucagon receptor/GLP-1 receptor dual agonist.

References
<p>[1]. Ie Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162-173.</p> <p>[2]. Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial [published correction appears in Diabetologia. 2024 Feb 13;]. Diabetologia. 2024;67(3):470-482.</p> <p>[3]. Klein T, Augustin R, Hennige AM. Perspectives in weight control in diabetes - Survodutide. Diabetes Res Clin Pract. 2024;207:110779.</p> <p>[4]. Zimmermann T, Thomas L, Baader-Pagler T, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022;66:101633.</p>